Herpes Zoster (Shingles) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000
Buy Report

Published: June 30, 2022 Report Code: GDGMDHC22219IDB-ST

Select Item

Shingles (herpes zoster) is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain, and swollen glands. The predisposing factors include age and a weakened immune system.

The Herpes Zoster (Shingles) pipeline drugs market research report provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Herpes Zoster (Shingles) (Infectious Disease) and features dormant and discontinued projects.

Herpes Zoster Pipeline Drugs Market by Key Targets

The targets of the Herpes Zoster pipeline drugs market are Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, Matrix Metalloproteinase 9, and Varicella zoster virus Envelope glycoprotein E.

Herpes Zoster Pipeline Drugs Market, by Targets

Herpes Zoster Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key Mechanism of Actions in the Herpes Zoster Pipeline Drugs Market

The mechanism of actions of the Herpes Zoster pipeline drugs market are Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, and Matrix Metalloproteinase 9 Inhibitor.

Herpes Zoster Pipeline Drugs Market, by Mechanism of Actions

Herpes Zoster Pipeline Drugs Market, by Mechanism of Actions

For more mechanism of action insights, download a free report sample

Key Routes of Administration in the Herpes Zoster Pipeline Drugs Market

The routes of administration in the Herpes Zoster pipeline drugs market are intramuscular, topical, parenteral, subcutaneous, and transdermal.

Herpes Zoster Pipeline Drugs Market, by Routes of Administration

Herpes Zoster Pipeline Drugs Market, by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Herpes Zoster Pipeline Drugs Market

The molecule types in the Herpes Zoster pipeline drugs market are subunit vaccine, small molecule, DNA vaccine, mRNA vaccine, recombinant protein, recombinant vector vaccine, synthetic peptide, vaccine, live attenuated vaccine, and monoclonal antibody.

Herpes Zoster Pipeline Drugs Market, by Molecule Types

Herpes Zoster Pipeline Drugs Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Herpes Zoster Pipeline Drugs Market

Some of the key companies in the Herpes Zoster pipeline drugs market are GC Biopharma Corp, Jiangsu Recbio Technology Co Ltd, Adjuvance Technologies Inc, AIM Vaccine Co Ltd, Amytrx Therapeutics Inc, Beijing Green Bamboo Biotechnology Co Ltd, Beijing Northland Biotech Co Ltd, BioNTech SE, CanSino Biologics Inc, and CHA Vaccine Institute Co Ltd.

Herpes Zoster Pipeline Drugs Market, by Companies

Herpes Zoster Pipeline Drugs Market, by Companies

To know more about the companies, download a free report sample

Herpes Zoster Pipeline Drugs Market Report Overview

Key Targets

 Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, Matrix Metalloproteinase 9, and Varicella zoster virus Envelope glycoprotein E
Key Mechanism of Actions Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, and Matrix Metalloproteinase 9 Inhibitor
Key Routes of Administration Intramuscular, Topical, Parenteral, Subcutaneous, and Transdermal
Key Molecule Types Subunit Vaccine, Small Molecule, DNA Vaccine, mRNA Vaccine, Recombinant Protein, Recombinant Vector Vaccine, Synthetic Peptide, Vaccine, Live Attenuated Vaccine, and Monoclonal Antibody
Key Companies GC Biopharma Corp, Jiangsu Recbio Technology Co Ltd, Adjuvance Technologies Inc, AIM Vaccine Co Ltd, Amytrx Therapeutics Inc, Beijing Green Bamboo Biotechnology Co Ltd, Beijing Northland Biotech Co Ltd, BioNTech SE, CanSino Biologics Inc, and CHA Vaccine Institute Co Ltd

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Herpes Zoster (Shingles) (Infectious Disease).
  • Reviews of pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews of key companies involved in Herpes Zoster (Shingles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • Evaluation of Herpes Zoster (Shingles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Adjuvance Technologies Inc
AIM Vaccine Co Ltd
Amytrx Therapeutics Inc
Beijing Green Bamboo Biotechnology Co Ltd
Beijing Northland Biotech Co Ltd
BioNTech SE
CanSino Biologics Inc
CHA Vaccine Institute Co Ltd
Changchun Bcht Biotechnology Co Ltd
Chengdu Maikekang BioTechnology Co Ltd
China National Pharmaceutical Group Corp
Chongqing Zhifei Biological Products Co Ltd
CPL Biologicals Pvt Ltd
DongKoo Bio & Pharma Co Ltd
Dynavax Technologies Corp
EyeGene Inc
GC Biopharma Corp
GeneOne Life Science Inc
GreenLight Biosciences Holdings PBC
GSK plc
Jiangsu Recbio Technology Co Ltd
NAL Pharmaceuticals Ltd
NanoViricides Inc
Shanghai Yidao Biological Technology Co Ltd
Shulov Innovative Science Ltd
SK Bioscience Ltd
Vaccitech Plc
Vapogenix Inc
XBiotech Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Herpes Zoster (Shingles) – Overview

Herpes Zoster (Shingles) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Herpes Zoster (Shingles) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Herpes Zoster (Shingles) – Companies Involved in Therapeutics Development

Herpes Zoster (Shingles) – Drug Profiles

Herpes Zoster (Shingles) – Dormant Projects

Herpes Zoster (Shingles) – Discontinued Products

Herpes Zoster (Shingles) – Product Development Milestones

Featured News & Press Releases

May 16, 2022: NanoViricides reports update on Shingles drug

Jan 07, 2022: Adjuvance Technologies announces issuance of U.S. patent covering semi-synthetic saponin adjuvants

Mar 30, 2021: Curevo Vaccine announces the approval to conduct a phase 1b clinical trial in South Africa to evaluate safety and immunogenicity of its adjuvanted subunit investigational vaccine, CRV-101, against varicella (Chickenpox) in HIV-positive children

Sep 15, 2020: Curevo Vaccine announces robust antibody response results of Phase I clinical trial of investigational vaccine for Shingles CRV-101

May 14, 2020: NanoViricides provides update on drug candidate NV-HHV-101

Jan 09, 2020: NanoViricides successfully completes required genetic toxicology testing of lead Drug candidate NV-HHV-101

Jan 07, 2020: NanoViricides has initiated genetic toxicology testing required for an IND for its drug candidate

Dec 06, 2019: NanoViricides annual meeting of shareholders to be held on Saturday, December 7th, 2019 at the Sheraton Hotel, Stamford, CT

Dec 03, 2019: NanoViricides founder Dr. Diwan provides $2,000,000 loan commitment to the company

Dec 02, 2019: NanoViricides has initiated required safety pharmacology assessment of lead drug candidate towards IND

Nov 19, 2019: NanoViricides files quarterly report for period ending September 30, 2019 – HerpeCide drug candidate ind enabling studies update, progressing towards clinical trials

Oct 31, 2019: NanoViricides initiates required dermal sensitization and ocular irritation testing of lead drug candidate towards IND

Oct 09, 2019: NanoViricides has initiated bio-analytical studies as part of IND-enabling safety and toxicology studies of lead candidate NV-HHV-101

Oct 03, 2019: NanoViricides is creating nanomedicines to develop antiviral therapies to combat shingles and herpes viruses

Sep 26, 2019: Curevo Vaccine announces interim results of phase I clinical trial of CRV-101

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

Herpes Zoster (Shingles) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Infectious Disease reports
Pharmaceuticals
New
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Herpes Zoster (Shingles) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Herpes Zoster (Shingles) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more